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Abstract
The acidic C-terminal peptides from Trypanosoma cruzi ribosomal P proteins
are the major target of the antibody response in patients suffering Chagas
chronic heart disease. It has been proposed that the disease is triggered by
the cross-reaction of these antibodies with the second extra cellular loop of
the 1-adrenoreceptor, brought about by the molecular mimicry between
the acidic C-terminal peptides and the receptor's loop. To improve the
understanding of the structural basis of the autoimmune response against
heart receptors, the 3-dimensional structure of the C-terminal peptides of
Trypanosoma cruzi ribosomal proteins P0 (EDDDDDFGMGALF) and P2
(EEEDDDMGFGLFD) were solved using the Electrostaticaly Driven
MonteCarlo method. Their structures were compared with the second
extra-cellular loop of our homology model of human rhodopsin and the
existing experimental NMR structures of the C-terminal peptides from
human P0 (EESDDDMGFGLFD) and from Leishmania braziliensis P0
(EEADDDMGFGLFD). Docking of Trypanosoma cruzi peptides P0, P2 and
human rhodopsin loop into our anti-P2 monoclonal antibody homology
model allowed to explore their interactions.
The solution structure of peptides P0 and P2 can be briefly described as a
bend. Although the global conformations of the peptides are not identical
they shared a common region of four residues (3 to 6) that have a similar
structure. The structural alignment of the five peptides also showed a
surprising conformational similarity for the same residues. The antibody
model and docking studies revealed a most remarkable feature in the active
site, a positively charged, narrow and deep cavity where the acidic residues 3
to 6 were accommodated. These results suggest that the most important
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elements in the molecular peptide recognition by the antibody may be the
shape of the loop and the presence of negative charges in positions 3–5 (P0,
P2) or a negative charge in position 4 (rhodopsin loop). This work describes
clearly the interactions of the structural elements involved in the autoimmune
mechanism of anti-P auto-antibodies cross-reaction and stimulation of the 1-
adrenoreceptor and the visual pigment rhodopsin. Results from this study
could lead eventually to the development of treatments to abolish receptor
mediated symptoms in Chagas. PACS code: 87.15.-v
1. Introduction
The Chagas disease or American tripanosomiasis is a parasitosis produced by the flagellated pro-
tozoa Trypanosoma cruzi. It is transmitted by the insect vector Triatoma infestans. According to a
recent report of the Scientific Working Group on Chagas Disease the overall prevalence of human
Trypanosoma cruzi infection is estimated at 16–18 million cases. Approximately 120 million peo-
ple or 25% of Latin American inhabitants are at risk of contracting the infection.
People infected with Trypanosoma cruzi may suffer cardiac, gastrointestinal or neurological
damage. Although disease manifestations vary widely from one area to another, it is estimated
that 25–30% of the infected people will progress to irreversible cardiac, oesophageal and colonic
pathologies, causing considerable morbidity and mortality [1].
Chagas's chronic heart disease (cChHD) is a myocarditis characterized by arrhythmia, tachy-
cardia and heart failure. In the chronic phase of the disease, patients present antibodies against
the acidic rich C-terminal of Trypanosoma cruzi ribosomal P proteins [2]. It has been proposed
that cChHD is an autoimmune disease produced by the existence of molecular mimicry between
the C-terminal of ribosomal P proteins and the second extra cellular loop of the 1-adrenergic
receptor (H26R) [3].
Ribosomal P proteins are a protein complex which forms the long and protruding region
called the stalk in the large ribosome subunit. In eukaryotes the P family encompasses protein P0
(34 kD), P1 and P2 (~10 kD) [4]. A third protein, P3, has been found in plants [5]. The number
of proteins in the P1 and P2 families varies among species. In mammals, insects and fungus, the
complex is formed by P0 and two copies of P1 and P2 [6,7]. Yeast and protozoa like Trypanosoma
cruzi have five members: P0, P1, P1, P2 and P2 [8-10]. All of them have a conserved acidic
motif in the C-terminal end and show high sequence identity with the last one hundred amino
acids of P0 C-terminal.
P013 (EDDDDDFGMGALF) and R13 (EEEDDDMGFGLFD) are the peptides corresponding
to the last 13 amino acids of Trypanosoma cruzi P0 and P2 respectively and a major target of the
humoral immune response against the parasite [2].PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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The active immunization with P0 and P2 recombinant proteins from Trypanosoma cruzi has
been shown to induce stimulation of the 1-adrenoreceptor in murine models. This activity has
been correlated with ventricular arrhythmia, abnormal repolarizations and conduction defects
[11]. Moreover, it has been proved that monoclonal antibodies against H26R induce apoptotic
effects in cardiomyocites [12]. Another study has associated the dysfunction of the retina, suf-
fered by chagasic patients, with a similar autoimmune mechanism in which anti-P auto-antibod-
ies would cross-react with the visual pigment rhodopsin [13].
A preliminary study of the cross reaction between the anti-P2 monoclonal antibody
(mAb17.2) and the 1-adrenergic receptor was done by Smulski et al. [14]. They prove that an
antibody induced by a Trypanosoma cruzi intracellular protein has the ability to bind a peptide
which is part of the extracellular domain of a human cardiac receptor. Although such results
include a paragraph about molecular modelling studies describing the manual docking of mini-
mized structures of charged hepta peptides from P2 C-terminal (EDDDMGF) and the second
extra cellular loop of the 1 adrenergic receptor (ESDEARRCYN) into an homology model of the
antibody, they did not report detailed interaction studies.
The aim of this work is to contribute to a deeper understanding of the molecular basis of Cha-
gas's chronic heart disease through the structural study of the C-terminal peptides and their inter-
action with the homology model of the anti-P2 monoclonal antibody(mAb17). The solution
conformation structures of peptides P013 and R13 are the result of the global optimization of
the all atom force-field ECEPP/3 plus implicit hydration models using the EDMC method (Elec-
trostatically Driven Monte Carlo) [15,16].
The EDMC structures were compared with the experimental NMR structures of human P0
H13, PDB code 1S4J (EESDDDMGFGLFD), Leishmania braziliensis P0 A13, PDB code 1S4H
(EEADDDMGFGLFD) [17], and SEL (RYIPEGLQCSCGIDYYTLKPEVNNES), the second extra-
cellular loop of our human rhodopsin homology model.
The conformational study of the antigen-mAb17.2.2 interaction can be divided in three steps:
1) Conformational search to define the three dimensional structure of R13 and P013.
2) Homology modeling of rhodopsin and monoclonal antibody mAb17.2
3) Molecular docking. The antigen-antibody interaction was analyzed through the docking
of the different peptides onto the target antibody mAb17.2PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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2. Methods
2.1. Conformational search
Electrostaticaly driven Monte Carlo (EDMC). The first step consisted in generating feasible target
peptide conformations using the EDMC method. The method combines stochastic Monte Carlo
algorithms and the optimization of the electrostatic interactions, whereby the molecule evolves
toward conformations in which the charge distribution becomes energetically more favourable.
2.2. Evaluation of the Conformational Energy
An all-atom chain representation was used with the ECEPP3 force field [18-22]. Two alternative
forms of the potential energy function were used to evaluate the total energy during the confor-
mational search. One, in vacuum corresponding to the ECEPP/3 force field and the other adding
a simple solvent interaction model of surface accessibility [23-25].
2.3. The Starting Point and conformational search
The amino and carboxyl termini of the target fragment of the P protein molecule were blocked
by amino-COCH3 and carboxyl-NH2 groups, respectively. An ensemble of conformations was
generated for each peptide starting from (I) canonical -helix, assigning the values (-60°,-40°)
to dihedral angles (,) of each amino acid residue, while keeping all values of  to 180°. (II)
polyproline conformation, assigning the values (-80°,150°) to dihedral angles (,) of each
amino acid residue, while keeping all values of  to 180° (III) canonical -strand, assigning the
values (-139°,135°) to dihedral angles (,) of each amino acid residue, while keeping all val-
ues of  to 180° (IV) Random conformation, the simulations were started from two different
initial random conformations, for each of these random conformations, all backbone and side-
chain dihedral angles were chosen randomly between 180.0° and -180.0°, with the exception of
the dihedral angles  of the peptide group, which were always chosen in the trans (180.0°) con-
formation. All backbone and side-chain dihedral angles were allowed to vary freely during the
simulations.
2.4. pH conformational coupling
Many research groups [22,26-31] have devoted a large amount of effort to develop fast and reli-
able algorithms provide a solution to the problem of ionization equilibrium. However, the incor-
poration of these algorithms into conformational searches of short peptides is computationally
too time consuming. Here, we used an alternative approach in which the energy of the whole
ensemble of conformations, generated in a conformational search, is re-evaluated by considering
the problem of ionization equilibrium at a given pH explicitly [32]. This methodology permitted
us to compute the average degree of charge to each of the ionizable groups in the sequence.
Allowing us to find out the importance and influence of the ionizable groups in the peptides, the
influence of solvent polarization effects and electrostatic interactions in the discrimination of the
lowest-energy conformation.PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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The evaluation of the conformational energy follows the procedure previously published [22].
The total free energy E(rp, pH) associated with the conformation, rp, of the molecule in aqueous
solution at a given pH, is defined by considering a three-step thermodynamic process: cavity cre-
ation, polarization of the solvent, and alteration of the state of proton binding. This free energy
involved in transferring the neutral peptide from the gas phase to the aqueous solution is given
by:
Where Eint(rp) is the internal conformational energy of the molecule in the absence of solvent,
corresponding to the ECEPP/3 energy of the neutral molecule [18-22]; Fvib(rp) is the conforma-
tional entropy contribution calculated by the harmonic vibrational contribution with zero
charge [33,34]. Fcav(rp) is the free energy associated with the process of cavity creation when trans-
ferring the molecule from the gas phase into the aqueous solution; this term is proportional to
the solvent accessible surface of the molecuele. Fsolv(rp) is the free energy associated with the
polarization of the aqueous solution calculated by using the Multigrid Boundary Element
method developed by Vorobjev and Scheraga [31]. Finz(rp, pH) is the free energy associated with
the change in the state of ionization of the ionisable groups due to the transfer of the molecule
from the gas phase to the solvent at a fixed pH value. This energy is calculated by using the general
multi-site titration formalism [26,28]. This approximation computes the 2
N ionization states,
where N is the total number of ionisable groups. The present method provides an accurate calcu-
lation of the potential of mean forces between ionized groups of the protein and the pK shifts of
the ionisable groups as a function of the peptide environment.
2.5. Homology Modeling
First, the structure of the mAb17.2 Fv domain was modelled with MODELLER [35], using as tem-
plate the PDB code 1NBV (82% sequence identity). PDB code 1S5I was used to model the heavy
chain CDR3 (TYWGQGTLVTVS, 100% sequence identity). BLAST [36] and T-Coffee [37] were
used to search for the templates and perform the alignment, respectively.
Second, the model of human rhodopsin was generated in a similar way using the bovine rho-
dopsin structure as template (PDB 1U19, 93% sequence identity). The quality of the models was
assessed by the WHAT_CHECK standalone program [38].
2.6. Docking
The docking of peptides R13, P013 and SEL into mAb17.2 was done using BIGGER (Biomolecu-
lar complex Generation with Global Evaluation and Ranking) implemented on Chemera 2.0
[39]. BIGGER has a soft docking algorithm, an intermediate approach between flexible and rigid
docking. The flexibility of the side chains was treated in a crude implicit way by allowing partial
superposition of the side chains. Default options were used except for the angular step that was
Er p H E r F r F r F r F r p H pp v i b p c a v p s o l v p i n z p (, ) () () () () (, ) int =++++PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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set at 12°. For R13, 5000 putative complexes were generated and then clustered using a 2.5 Å
RMSD. P013 was treated in the same way. About 8000 complexes were generated with full length
rhodopsin and then clustered using a 2.5 Å RMSD. An additional score based on the distance
from the amino acids of the probe to the amino acids of the CDRs was generated. In order to
discard unreal solutions, the best results were analysed visually. Three results were chosen for
rhodopsin. For the R13 and P013 peptides the final sets were around 15 possible solutions. The
final complexes were minimized using the Polak-Ribiere conjugate gradient method using the
AMBER99 force field [40]. The value of the potential energy, visual analysis and the comparison
among all the different docking runs allowed the selection of just one ligand-antibody complex.
They were submitted, for further refinement, to a simulated annealing protocol using the molec-
ular dynamic software NAMD [41].
2.7. Docking Refinement
The complexes obtained from molecular docking were submitted to a regular molecular dynam-
ics simulation with NAMD [41] of 7.5 ns, at 300 K, allowing the whole system to move. This sim-
ulation did not show significant changes with respect to unrefined docking results.
The next step was to refine the complexes obtained from the molecular docking, using simu-
lated annealing through molecular dynamics simulation with the software NAMD [41]. The
parameters of the simulation were optimized, through shorts runs, allowing all system parame-
ters to move.
The optimized protocol was as follows: the system was solvated using a sphere of TIP3 [42]
water model. Spherical boundary conditions were applied to avoid the evaporation of water mol-
ecules. The motion of the antibody was restricted, allowing only the CDRs residues to move. A
langevin piston [43,44] was implemented to keep the pressure at 1 atm. The regulation of the
temperature was enforced by a langevin thermostat [45]. An integration time step of 2 fs was
used. The simulation started at 300 K and the whole system was heated up to 600 K by 50 K
jumps every 10 ps. Then, the temperature was held at 600 K during 120 ps. Afterwards, the tem-
perature was decreased by 50 K jumps. The first jump was done after 10 ps, the second one after
20 ps, then 40 ps, 60 ps and 100 ps. Then, the system was kept at 300 K during 160 ps. The whole
process was iterated three times.
3. Results
3.1. Peptide structure
The structure of P013 (EDDDDDFGMGALF) was calculated as explained in the methods section.
The whole conformational search carried out produced almost 12000 conformations. The lowest
energy conformation, shown in Figure 1a, had a much lower energy values than the rest of the
solutions. The average degree of charge state per residue was determined using the coupling
between the conformations versus the pH model. The Boltzmann average over all the conforma-
tions was completely determined by the lowest energy conformation. It was found that at pH 7PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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only one out of six chargeable amino acids is neutral despite the proximity of these residues
among themselves (see figure 1b).
The structure of P013 can be briefly described as a bend in which the five negatively charged
residues (E1, D3, D4, D5, D6) are pointing towards the solvent. The uncharged D2 is interacting
with M9 which is in a cluster of residues that form a kind of hydrophobic core (F7, G8, M9, G10,
A11, L12 and F13).
The EDMC of the R13 (EEEDDDMGFGLFD) can be also described as a bend. The lowest
energy conformation out of the 12000 conformation sample is shown in Figure 2a. In this case,
the average degree of charge state per residue at pH 5 and pH 7 was determined, showing that E1
and D4 were uncharged. The minimum energy conformations were the same at both pHs. At pH
7 the energy was slightly lower and the mean charge state was slightly different (Figure 2b). As
we saw with P013, the result of the Boltzmann average is entirely determined by the lowest
energy conformation. The reason for calculating the structure at pH 5 was to compare our results
directly with the ones obtained by the NMR studies of this peptide by Soares et al [17]. They
found that R13 behaves as a random coil in solution, and that the binding to antibody reduces
the peptide flexibility, inducing a more defined conformation. We found that both, P013 and
R13, are bends. It is possible to argue that the flexibility of R13 hinders the assignment of a
defined structure. We could report a definite structure because in our method we only analyzed
the minimum energy conformation without taking into account the flexibility of the peptides.
Structure of P013 peptide Figure 1
Structure of P013 peptide. A) Representation of theoretical minimum energy conformation of P013 peptide. 
Amino acids are labeled using one-letter code. B) Boltzmann average degree of charge in accord with the conforma-
tional pH model. Only D2 is uncharged at pH7.PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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3.2. Conformational comparison of P013, R13, H13, A13 and rhodopsin
Superposition of P013 and R13 showed that they were quite similar in the curved region of the
bend (residues 3 to 6) while the conformation for the rest of the residues was different. The next
step was to compare them with SEL (the second extra-cellular loop of our homology model of
human rhodopsin, based on the bovine crystal structure) and the experimental NMR structures
of H13 (PDB code 1S4J) and A13 (PDB code 1S4H). The structural alignment RMSD values,
against R13, can be seen in Figure 3a. The structural alignment of the five peptides showed a sur-
prising conformational similarity to residues 3 to 6 (Figure 3b).
Experimental data demonstrated that the affinity of these peptides towards monoclonal anti-
body 17.2 follows the order R13 > H13  P013 > A13 [14,17]. Remarkably, their conformational
differences, which are reflected in the RMSD values of the structural alignment, followed an iden-
tical order suggesting that there may be a correlation between the conformation of the bend and
its affinity. See figure 3.
Another important outcome was finding out that SEL13, a portion of the second extra cellular
loop of rhodopsin, has a matching shape in spite of not having sequence identity with these pep-
tides. This fact strongly reinforces the results of studies that have associated the dysfunction of
the retina in chagasic patients with an autoimmune mechanism in which anti-P auto-antibodies
would cross-react with the visual pigment rhodopsin [13]. Our findings also support one of the
conclusions of a previous study by Soares et al. [17] about the importance of the conformational
state in the peptide-antibody interaction.
Structure of R13 peptide Figure 2
Structure of R13 peptide. A) Representation of the theoretical minimum energy conformation of R13 peptide. 
Amino acids are labelled using one letter code. B) Boltzmann average degree of charge in accord with the confor-
mational pH model, light gray pH 5, dark grey pH 7. At both pHs values the uncharged residues are E1 and D4.PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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3.3. Structure of antibody mAb17.2 Fv domain and Antibody-peptide docking analysis
The electrostatic potential surface of the antibody revealed that the antigen-binding site, formed
by the six CDR loops from the two variable chains, is a positively charged depression with a small
and narrow cavity at the bottom. See Figure 4.
Structural alignment of the five peptides Figure 3
Structural alignment of the five peptides. A) RMSD values resulting from the structural alignment of P013 
(green), H13 (orange), A13 (grey) and 2° rhodopsin loop (blue) all against R13 peptide, using a 4 residue sliding win-
dow. B) Superimposition of R13 (red), P013 (green), H13 (orange), A13 (gray) and 2° rhodopsin loop (blue). Only 
the underlined residues are shown (insert).PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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The docking of the R13 peptide into the antibody showed that the curve formed by E3, D4,
D5 and D6 binds very deeply into the cavity while the residues forming the hydrophobic core
(residues 7 to 13) were associated with the first hypervariable loop of the light chain.
The most dominating feature of the docking is the neutralization of the charged residues in
the peptide through the formation of ion pairs between R50 (CDR2, heavy chain) and E3 plus
R52 (CDR2, heavy chain) with D5 and D13. D6 is pointing towards the solvent. See figure 4.
These interactions were observed before and after the refinement process, except in the case of
D13 which after the refinement, and due to the elongation of the peptide, is now pointing
towards the solvent, as can be seen figure 5.
Other observed electrostatic interactions were of the hydrogen bond type. E2 backbone carb-
onyl is hydrogen bonded to R165 (light chain) and G101 (heavy chain). E3 hydroxyl is hydrogen
bonded to Y215 hydroxyl (light chain) D4 is forming and hydrogen bond with L152 and G210
(light chain).
The docking of the P013 peptide showed that the bend residues (3 to 6) bind similarly but
less deeply than R13. D3 and 5 are again neutralized by R50 and 52 (heavy chain). The main
difference observed when comparing electrostatic interactions between these two peptides is the
ion pair formed between D4, which is unprotonated in P013, and R165 (light chain). The
remaining residues (7 to 13) are exposed to the solvent instead of interacting with the CDR1 of
the light chain as in the case of R13.
Top-side view of R13 and P013 bonded to mAb17.2 Figure 4
Top-side view of R13 and P013 bonded to mAb17.2. The antibodies residues (orange) are depicted using the 
stick representation and labelled using one-letter code, the most relevant residues are shown. The thin line corre-
sponds to R13 (red) and P013 (green).PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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The results obtained directly from the docking of the P013 peptide (without refinement)
showed that the bend residues 3 to 6 bind similarly but less deeply than R13. After the refine-
ment, the curved region (residues 3 to 6) becomes less curved and there is a change in the relative
position of the C terminal with respect to the antibody, this is shown in figure 5. The E1 back-
bone carbonyl is forming a hydrogen bond with the side chain amide nitrogen of K149 (light
chain). D2, D4, D5 and D6 are neutralizing K172, R165 (both at the light chain), R50 and R52
(both at the heavy chain), respectively. The remaining residues (7 to 13) are exposed to the sol-
vent. See figure 6.
Another difference observed between the interactions of the two peptides with the antibody
is the variation of the solvent accessible surface between the free and the docked state. The change
in the solvent accessible surface was 10% for P013 and 13% for R13 after refinement. This param-
eter is a measure of the entropy increase in the complex formation and is given by the water mol-
ecule exclusion in the interaction surface.
Refinement of R13 docking results Figure 5
Refinement of R13 docking results. Cartoon representation of the result of the docking analysis and the refine-
ment procedure. Antibody is coloured orange, and R13 peptide is red. From left to right and top to bottom, the 
docking result without refinement, a snapshot of the MD trajectory after one cycle of heating and and cooling, a 
snapshot after two cycles and finally the last snapshot after the whole procedure was done.PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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The third docking study was about rhodopsin (this complex was not refined due to the size of
the system). It was found that the residues PEVN of the second extra cellular loop bind in a sim-
ilar fashion as to residues 3 to 6 in the R13-P013 complexes. Rhodopsin E197 is occupying the
same position as E3 in the R13 complex. It is stabilized by the formation of two ions pairs: the
first with R50 (heavy chain), remaining in the same conformation as it had in the previous com-
plexes, and the second with R52 (heavy chain), which has moved from the position it had in the
R13 complex being now in a conformation that allows the interaction with E197.
4. Discussion
The first part of the study concerning the calculation of peptide structures by theoretical methods
and their comparison with existing NMR and crystal structures reveals a most important com-
mon feature. Namely the curve formed by residues 3 to 6 having a surprising conformational
similarity. Remarkably, the affinity of these peptides towards the antibody, following the order
R13 > H13  P013 > A13 according to previous experimental work of Smulski et al [14] and
Refinement of P013 docking results Figure 6
Refinement of P013 docking results. Cartoon representation of the result of the docking analysis and the 
refinement procedure. Antibody is colored orange, and P013 peptide is green. From left to right and top to bottom, 
the docking result without refinement, a snapshot of the MD trajectory after one cycle of heating and and cooling, a 
snapshot after two cycles and finally the last snapshot after the whole procedure was done.PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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Soares et al [17], is reflected in the order of the conformational differences of the peptides with
respect to R13, according to the present work.
In the second part of our work, which involved the modelling of the mAb17.2 Fv domain,
based on the crystal structure of a high sequence identity auto-antibody to single stranded DNA,
the most remarkable feature was the positively charged, narrow and deep cavity in the active site
fitting the bend formed by residues 3 to 6 [46]. See figure 7.
The third and final part of this study was the docking of R13, P013 and rhodopsin into the
mAb17.2 Fv homology model. The analysis of the interactions indicates the residues which may
play a crucial part in the process of the molecular recognition. The results suggest that residues 3
to 5 might act as an anchor. Once the bend is bound, the rest of the peptide may undergo major
conformational changes allowing a tighter binding in an induced-fit fashion. P013 (before and
after the refinement) seems to bind more loosely than R13. This fact is in qualitative accordance
with the experimental measured affinities. Finally, the docking of rhodopsin shows that the only
charged residue in the loop, E197, is occupying the place of E3 and is stabilized by R50 and 52.
Relevant binding residues Figure 8
Relevant binding residues. Relevant binding residues found for the binding of P013, R13 peptide and Rhodopsin 
to mAb 17.2 are highlighted in red.
Top view of mAb 17.2 Fv model Figure 7
Top view of mAb 17.2 Fv model. The van der Waals surface is coloured according to the electrostatic potential 
calculated with the program Poisson-Boltzman electrostatics calculated using APBS [46] as implemented in PyMol, 
using default charge values and dielectric constant 80 (Receptor coloured by calculated charge from red -1 to blue 
+1). The binding site of the peptide is a positive charged cavity. Inferior view of R13. The peptide has been moved 
off the binding site and rotated 180 degrees.PMC Biophysics 2009, 2:4 http://www.physmathcentral.com/1757-5036/2/4
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Our model suggests that the most relevant elements in the molecular recognition of the peptides
by the antibody are the shape or conformation of the bend combined with the presence of neg-
atively charged residues in position 3 and 5 (P013 and R13), or one in position 4, as it is the case
in rhodopsin, figure 8. Our results support the existence of the anti-P auto-antibodies cross-reac-
tion and provide a "molecular in silico characterization" for previously reported experiments.
5. Conclusion
The outcome from this study clearly describes the interactions of the structural elements involved
in the autoimmune mechanism of anti-P auto-antibodies cross-reaction, the stimulation of the
1-adrenoreceptor and the visual pigment rhodopsin. It also gives us some qualitative ideas to
judge the potential binding of the anti-P auto-antibodies to receptor loops in different tissues.
Results from this study may eventually lead to the development of treatments to abolish receptor
mediated symptoms of Chagas's disease and other autoimmune pathologies.
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